Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851284 | 0.76 | RAB9A (0.51) | P2RX7KMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6850893 | 0.75 | KMT2A (0.49) | EPHX1EPHX2P2RX7KMT2ASMN1; SMN2 | |
| SCHEMBL6849668 | 0.74 | HPGD (0.51) | P2RX7KMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6849680 | 0.74 | LMNA (0.56) | EPHX2P2RX7KMT2A | |
| SCHEMBL7099342 | 0.72 | JAK3 (0.39) | — | |
| SCHEMBL6846858 | 0.71 | LMNA (0.43) | EPHX1P2RX7KMT2AMEN1 | |
| SCHEMBL6846989 | 0.70 | SIGMAR1 (0.48) | KMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7094424 | 0.70 | MTNR1A (0.49) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6846909 | 0.70 | LMNA (0.45) | EPHX1EPHX2CCR2 | |
| Hydrochloric Acid SCHEMBL7096357 | 0.69 | LMNA (0.44) | EPHX1EPHX2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | EPHX1 628/4885EPHX2 1125/4885CCR2 707/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | EPHX1 628/4885EPHX2 1125/4885CCR2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.